A Phase 3 interventional study of Triptorelin (Decapeptyl®) in Prostate Cancer, sponsored by Ipsen. Completed at 59 sites in 10 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-01-30.
Sponsored by Ipsen · Phase 3, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 28 studies testing triptorelin in Prostatic Neoplasms — 6 open to participants now, 6 under way, 3 of them phase 3. triptorelin · Prostatic Neoplasms.
Among the 28 studies testing triptorelin in Prostatic Neoplasms, this one is the 5th largest by enrollment, is the only one that started in 2009, is one of 12 in phase 3, and was the 7th registered.
7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,579 are open to participants now.
Browse Prostatic Neoplasms studies →6 of the 28 studies testing triptorelin in Prostatic Neoplasms are open now, in 5 countries. Recruiting first, the newest first:
Baptist Health South Florida · Sites in United States
Ages 18+ · Men only
Cancer Research Antwerp · Sites in Belgium
Ages 18+ · Men only
Ottawa Hospital Research Institute · Sites in Canada
Ages 18+ · Men only
Instituto de Investigación en Oncología Radioterápica - Fundación Española de Oncología Radioterápic · Sites in Spain
Ages 18+
Marco Lorenzo Bonu · Sites in Italy
Ages 18–80 · Men only
By country, each count listing its studies:
triptorelin: first FDA approval 2000 (TRELSTAR). What it is approved for, and how studies give it, is on its page →
Of the 1,228 Prostatic Neoplasms studies recruiting now, 927 (75%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.
This study: 18 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
28 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 8 · Phase 3 13 · Phase 4 6
First in 2002; this study’s year is marked. 1 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 339 is above the median of 60 across 5,349 interventional studies indexed under Prostatic Neoplasms.
Median enrollment 120 across the 28 interventional studies. Of the 17 that completed or were terminated, 10 (59%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 28 have an industry lead sponsor. The 10 most frequent:
Ipsen is the lead sponsor of 289 studies on the registry; 17 are open to participants now.
Of its 26 completed or terminated interventional studies of FDA-regulated products, 22 (85%) have results posted.
26 studies in Prostatic Neoplasms by Ipsen: none open now, none under way, none of them phase 3. Of 26 finished, 12 (46%) have results posted.
Among the 26 studies in Prostatic Neoplasms by Ipsen, this one has the largest enrollment of the 16 interventional ones that give a count, is one of 2 that started in 2009, is one of 7 in phase 3, and was the 4th registered.
Ipsen’s Prostatic Neoplasms studies by the year they started, since 2006.
1 of the studies testing triptorelin in Prostatic Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05851547Ottawa Hospital Research InstituteDose Escalation For INtraprostatic LEsions | 2027-06 |
Add it to your calendar (.ics) → With an account.
Among the 28 studies testing triptorelin in Prostatic Neoplasms, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Ipsen’s 26 in Prostatic Neoplasms:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the effect of an initial hormonal treatment gonadotrophin-releasing hormone (GnRH Agonist) on 2 biomarkers (PCA3 and TMPRSS2-ERG), in patients with histologically confirmed and advanced stages of prostate cancer. Their characteristics, according to risk factors such as PSA and Gleason score will be determined at baseline and 1, 3 and 6 month post-treatment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Triptorelin (Decapeptyl®)
One intramuscular injection of triptorelin (Decapeptyl®) 22.5mg performed once all baseline procedures and assessments have been completed.
PCA3 Score Expressed as a Ratio of PCA3 mRNA (Messenger Ribonucleic Acid) Over PSA (Prostate Specific Antigen) mRNA
PCA-3 score = (mRNA PCA3/mRNA PSA)x1000 * Non-assessable = Associated PSA mRNA \<7500 copies/mL * ≤BLQ = PCA-3 mRNA is below the concentration of the calibrator and associated PSA mRNA \>7500 copies/mL * \<35 = PCA-3 mRNA above BLQ and less than 35 * ≥35 = PCA-3 mRNA greater or equal to 35
Time frame: At month 6 post-treatment
PCA3 Score Expressed as a Ratio of PCA3 mRNA Over PSA mRNA
PCA-3 score = (mRNA PCA3/mRNA PSA)x1000 * Non-assessable = Associated PSA mRNA \<7500 copies/mL * ≤BLQ = PCA-3 mRNA is below the concentration of the calibrator and associated PSA mRNA \>7500 copies/mL * \<35 = PCA-3 mRNA above BLQ and less than 35 * ≥35 = PCA-3 mRNA greater or equal to 35
Time frame: At month 1 and 3 post-treatment
TMPRSS2-ERG Score (Expressed as a Ratio of T2-ERG mRNA Over PSA mRNA)
TMPRSS2-ERG = (TMPRSS2-ERG mRNA / PSA mRNA) x 100000 A TMPRSS2-ERG score \<35 was described as 'negative' and a TMPRSS2-ERG score ≥35 as 'positive.'
Time frame: At baseline, month 1, 3 and 6 post-treatment
Proportion of Patients Medically Castrated (i.e. With Serum Testosterone Levels of <50 ng/dL)
Time frame: At month 1, 3 and 6 post-treatment
PSA Level
Time frame: At baseline, month 1, 3 and 6 post-treatment
Safety, Assessed Through the Collection of Adverse Events (AEs)
Time frame: For the duration of the study (up to month 6)
Study Initiation Date: 30-Nov-2009. Subjects screened were 339 and screen failures were 13.
| Milestone | Triptorelin (Decapeptyl®) 22.5 mg |
|---|---|
| Started | 339 |
| Completed | 326 |
| Not completed | 13 |
| Withdrew: Adverse event | 6 |
| Withdrew: Withdrawal by subject | 5 |
| Withdrew: Does not meet entry criteria | 2 |
| Milestone | Triptorelin (Decapeptyl®) 22.5 mg |
|---|---|
| Started | 325 |
| Completed | 299 |
| Not completed | 26 |
| Withdrew: Adverse event | 11 |
| Withdrew: Consent withdrawn | 3 |
| Withdrew: Disease progression | 2 |
| Withdrew: Lack of efficacy | 8 |
| Withdrew: Lost to follow-up | 2 |
PCA-3 score = (mRNA PCA3/mRNA PSA)x1000 * Non-assessable = Associated PSA mRNA \<7500 copies/mL * ≤BLQ = PCA-3 mRNA is below the concentration of the calibrator and associated PSA mRNA \>7500 copies/mL * \<35 = PCA-3 mRNA above BLQ and less than 35 * ≥35 = PCA-3 mRNA greater or equal to 35
| participants | Triptorelin (Decapeptyl®) 22.5 mg |
|---|---|
| Non-assessable | 232 |
| ≤BLQ | 27 |
| <35 | 10 |
| ≥35 | 24 |
| Missing - No sample analysis done | 5 |
PCA-3 score = (mRNA PCA3/mRNA PSA)x1000 * Non-assessable = Associated PSA mRNA \<7500 copies/mL * ≤BLQ = PCA-3 mRNA is below the concentration of the calibrator and associated PSA mRNA \>7500 copies/mL * \<35 = PCA-3 mRNA above BLQ and less than 35 * ≥35 = PCA-3 mRNA greater or equal to 35
| participants | Triptorelin (Decapeptyl®) 22.5 mg |
|---|---|
| Month 1: Non-assessable (N=322) | 109 |
| Month 1: ≤BLQ (N=322) | 40 |
| Month 1: <35 (N=322) | 80 |
| Month 1: ≥35 (N=322) | 91 |
| Month 1: Missing - No sample analysis done (N=322) | 2 |
| Month 3: Non-assessable (N=313) | 215 |
| Month 3: ≤BLQ (N=313) | 31 |
| Month 3: <35 (N=313) | 34 |
| Month 3: ≥35 (N=313) | 31 |
| Month 3: Missing - No sample analysis done (N=313) | 2 |
TMPRSS2-ERG = (TMPRSS2-ERG mRNA / PSA mRNA) x 100000 A TMPRSS2-ERG score \<35 was described as 'negative' and a TMPRSS2-ERG score ≥35 as 'positive.'
| participants | Triptorelin (Decapeptyl®) 22.5 mg |
|---|---|
| Baseline: Non-assessable (N=322) | 33 |
| Baseline: <35 negative (N=322) | 140 |
| Baseline: ≥35 positive (N=322) | 149 |
| Month 1: Non-assessable (N=322) | 117 |
| Month 1: <35 negative (N=322) | 97 |
| Month 1: ≥35 positive (N=322) | 106 |
| Month 1: Missing - No sample analysis done (N=322) | 2 |
| Month 3: Non-assessable (N=313) | 213 |
| Month 3: <35 negative (N=313) | 45 |
| Month 3: ≥35 positive (N=313) | 53 |
| Month 3: Missing - No sample analysis done (N=313) | 2 |
| Month 6: Non-assessable (N=298) | 241 |
| Month 6: <35 negative (N=298) | 24 |
| Month 6: ≥35 positive (N=298) | 27 |
| Month 6: Missing - No sample analysis done (N=298) | 6 |
| percentage of participants | Triptorelin (Decapeptyl®) 22.5 mg |
|---|---|
| Month 1 (N=322) | 94.7 |
| Month 3 (N=313) | 95.2 |
| Month 6 (N=298) | 90.9 |
| μg/L | Triptorelin (Decapeptyl®) 22.5 mg |
|---|---|
| Baseline (N=321) | 45.4 (1 to 12239) |
| Month 1 (N=320) | 8.3 (0 to 581) |
| Month 3 (N=311) | 1.8 (0 to 969) |
| Month 6 (N=296) | 1.2 (0 to 1251) |
| participants | Triptorelin (Decapeptyl®) 22.5 mg |
|---|---|
| Any Adverse Events (AEs) | 193 |
| Any Treatment Emergent Adverse Events (TEAEs) | 190 |
| TEAEs Leading to Withdrawal | 11 |
| TEAEs Leading to Death | 11 |
| Serious Adverse Events (SAEs) | 37 |
Collected over Up to month 6. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Triptorelin (Decapeptyl®) 22.5 mg | — | 37/325 (11.4%) | 89/325 (27.4%) |
| Event | Triptorelin (Decapeptyl®) 22.5 mg |
|---|---|
| FallInjury, poisoning and procedural complications | 2/325 |
| Heart failureCardiac disorders | 2/325 |
| Renal failureRenal and urinary disorders | 2/325 |
| Severe anemiaBlood and lymphatic system disorders | 2/325 |
| Bone pain due to metastasisNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 2/325 |
| Acute pneumoniaInfections and infestations | 2/325 |
| Acute respiratory failureRespiratory, thoracic and mediastinal disorders | 2/325 |
| Hip fractureInjury, poisoning and procedural complications | 1/325 |
| Chronic heart failureCardiac disorders | 1/325 |
| Perforated colonGastrointestinal disorders | 1/325 |
| Event | Triptorelin (Decapeptyl®) 22.5 mg |
|---|---|
| Hot flushVascular disorders | 89/325 |
| Age, Continuous(years) | Triptorelin (Decapeptyl®) 22.5 mg |
|---|---|
| Mean | 72.6 ± 8.4 |
| Sex: Female, Male(Participants) | Triptorelin (Decapeptyl®) 22.5 mg |
|---|---|
| Female | 0 |
| Male | 325 |
| Race (NIH/OMB)(Participants) | Triptorelin (Decapeptyl®) 22.5 mg |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 1 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 7 |
| White | 307 |
| More than one race | 0 |
| Unknown or Not Reported | 10 |
| Height(Cm) | Triptorelin (Decapeptyl®) 22.5 mg |
|---|---|
| Mean | 172.3 ± 6.5 |
| Weight(KG) | Triptorelin (Decapeptyl®) 22.5 mg |
|---|---|
| Mean | 79.6 ± 13.4 |
| BMI(kg/m²) | Triptorelin (Decapeptyl®) 22.5 mg |
|---|---|
| Mean | 26.79 ± 4.23 |
| PCA-3 Score(participants) | Triptorelin (Decapeptyl®) 22.5 mg |
|---|---|
| Non-assessable | 39 |
| ≤BLQ | 15 |
| <35 | 89 |
| ≥35 | 179 |
| Missing - No sample analysis done | 3 |
The record gives a start of Nov 2009, a primary completion of Nov 2011 and a completion of Jun 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2015, 3 years 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Triptorelin